Literature DB >> 3851693

Decreased monocyte-mediated cytostasis of human cancer cell in patients with lung cancer.

Y Nakata, J Yamashita, T Kishi, M Kataoka, T Ejiri, T Ohnoshi, I Kimura.   

Abstract

In vivo animal studies support the concept that monocytes and macrophages are important in the immune surveillance of oncogenesis and that in vitro activated murine macrophages are cytocidal for tumour cells. In this study, the tumour cell cytotoxic activity of human peripheral blood monocytes was examined by measuring the inhibition of 3H-thymidine uptake in the human cancer cell line, established in our laboratory from human squamous cell lung cancer. The monocytes from 8 of the 31 lung cancer patients (26%) showed a percentage growth inhibition of less than 69.8%, which exceeded the 95% confidence limits of the percentage growth inhibition observed with healthy control monocytes. On the other hand, among the 16 sarcoidosis and the 8 tuberculosis cases no value was below 69.8%. However, there was no significant difference between the growth inhibition and the clinical stages or histological type. When OK-432, a Streptococcal agent, was administered in vivo to patients with lung cancer, an elevation of the growth inhibition was observed in 7 out of 8 patients. It was confirmed that the tumour cell cytostatic activity of the monocyte is suppressed in patients with lung cancer, and these monocyte deficits hinder the inhibition of tumour growth and metastasis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3851693     DOI: 10.1007/bf00199772

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  Promotion of tumor growth in vivo by antimacrophage agents.

Authors:  R Keller
Journal:  J Natl Cancer Inst       Date:  1976-12       Impact factor: 13.506

2.  Macrophage content of tumours in relation to metastatic spread and host immune reaction.

Authors:  S A Eccles; P Alexander
Journal:  Nature       Date:  1974-08-23       Impact factor: 49.962

3.  Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages.

Authors:  I J Fidler
Journal:  Cancer Res       Date:  1974-05       Impact factor: 12.701

Review 4.  Corynebacterium parvum as an immunotherapeutic anticancer agent.

Authors:  M T Scott
Journal:  Semin Oncol       Date:  1974-12       Impact factor: 4.929

5.  Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: a preliminary report of clinical and biologic findings.

Authors:  L Israël; R Edelstein; A Depierre; N Dimitrov
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

6.  Cytotoxicity of cancer patient's macrophages for tumor cells.

Authors:  D J Cameron; P O'Brien
Journal:  Cancer       Date:  1982-08-01       Impact factor: 6.860

7.  Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin.

Authors:  G Peri; N Polentarutti; C Sessa; C Mangioni; A Mantovani
Journal:  Int J Cancer       Date:  1981-08-15       Impact factor: 7.396

8.  Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors.

Authors:  A Mantovani; N Polentarutti; G Peri; Z B Shavit; A Vecchi; G Bolis; C Mangioni
Journal:  J Natl Cancer Inst       Date:  1980-06       Impact factor: 13.506

9.  Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patients.

Authors:  T L Gerrard; J J Terz; A M Kaplan
Journal:  Int J Cancer       Date:  1980-11-15       Impact factor: 7.396

10.  An analysis of clinical and histopathological features in 101 cases of carcinoma of breast in women under 35 years of age.

Authors:  T G Brightmore; W P Greening; I Hamlin
Journal:  Br J Cancer       Date:  1970-12       Impact factor: 7.640

View more
  1 in total

1.  Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.

Authors:  S Sone; T Utsugi; P Tandon; H Yanagawa; A Okubo; T Ogura
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.